Description
Tapentadol is an atypical opioid drug used for the treatment of moderate to severe acute and severe chronic pain which can be managed only with opioids. It belongs to the opioid group of drugs, which can be broadly described as ‘depressant’ drugs in that their various clinical effects are in contrast to those produced by stimulant drugs. Tramadol is also an NRI, similar to non-stimulant ADHD medication atomoxetine.
Desirable Effects
- Pain relief
- Sedative
- Euphoria
- Relaxant
Undesirable Effects
- Headaches/dizziness
- Feeling/being sick
- Respiratory depression in combination with other depressants
What does it look like?
Tablets: Immediate release tablets are usually round, generally white or beige in colour at lower doses, and orange or pink at higher doses. Extended release tablets are usually oblong shaped, and come in white, blue-green and light blue colours.
Oral solution: A liquid usually containing 20 mg/mL tapentadol
Method of Use
Orally: swallowed as a tablet/capsule, drunk as a liquid solution
Pharmacology
Tapentadol is a full agonist at the mu (µ) opioid receptor (see Morphine for more details on opioid receptors) in the central and peripheral nervous systems.
Similar to tramadol, tapentadol also inhibits the recycling of neurotransmitter noradrenaline (NRI) which is thought to help alleviate neuropathic pain. However, tapentadol does not affect serotonin and is 2–3x more potent than tramadol at the µ-opioid receptor. Additionally, tapentadol doesn’t have any active metabolites making it more predictable.
Like tramadol, tapentadol can lower the threshold for seizures. Tramadol has also been shown to cause low blood pressure in some people.
Interactions
The combination of tapentadol with other depressants, such as alcohol and benzodiazepines, is associated with an increase in respiratory depression and overdose. Mixing tapentadol with antidepressants increases the risk of serotonin syndrome.
History
Tapentadol was first synthesised by chemist Helmut Buschmann and colleagues in the late 1980s at the German pharmaceutical company Grünenthal GmbH as a successor to tramadol with minimal serotonin activity. In 2010, the ACMD advised the UK government to control tapentadol as a Class A, Schedule II drug before it became available for clinical use. In May 2011, tapentadol was brought to the UK pharmaceutical market under the brand name Palexia for the treatment of severe chronic pain.
Between 2014 and 2022, as tramadol prescribing decreased, tapentadol prescriptions increased in England and Ireland by 179% and 389%, respectively. Additionally, some people seek tapentadol on the unregulated market either for recreational purposes or to self-medicate for unmet needs including pain. In recent years, tapentadol has been found as a contaminant in several samples from the UK’s unregulated drugs market including heroin, tramadol, modafinil, lorazepam, and morphine.
Law
Possible offences
- Possession
- Maximum sentence – 7 years imprisonment, a fine, or both
- Possession With Intent To Supply
- Maximum sentence – life imprisonment, a fine, or both
- Supply (including being concerned in supply, conspiracy to supply, aggravated supply and offer to supply)
- Maximum sentence – life imprisonment, a fine, or both
- Production
- Maximum sentence – life imprisonment, a fine, or both
In practice maximum sentences are rarely used, for more detailed and accurate information go to our sentencing page.